Jiaxi Li

Jiaxi Li


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2023 in Journal of Interferon & Cytokine Research
Verified
Journal Article
Closed access
YWYang Wang
Yang Wang
QWQi Wang
Qi Wang
TYTong Wang Yang
Tong Wang Yang
JYJi Ming Yin
Ji Ming Yin
FWFeili Wei
Feili Wei
DCDexi Chen
Dexi Chen
Chronic liver injury eventually progresses to cirrhosis and end-stage liver disease (ESLD), which are the leading causes of death in patients with liver disease worldwide. ESLD has a variety of etiologies and a complex pathogenesis. This study analyzed the characteristics of ESLD by studying the immune microenvironment and inflammatory microenvironment of ESLD caused by 4 noncancer diseases, including HBV-ALF, ALF, AILD, and AH. We collected transcriptome data from noncancer ESLD patients, collected liver tissue samples and blood samples from ESLD liver transplant patients, and analyzed the immune and inflammatory microenvironments in the liver and blood. The results showed that with the exception of HBV-induced ESLD, there were no significant differences in immune microenvironment scores among patients with ESLD caused by other noncancer diseases. Moreover, there were no significant differences in the inflammatory microenvironment in the liver and blood of patients with ESLD caused by the 4 noncancer diseases. Furthermore, we found that the cytokine, IL-15, could predict the prognosis of ESLD patients.

13 January 2025 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
LZLongxiao Zhang
Longxiao Zhang
YZYunfei Zhou
Yunfei Zhou
ZYZhongbo Yang
Zhongbo Yang
LJLiangchao Jiang
Liangchao Jiang
XYXinyang Yan
Xinyang Yan
JSJinning Song
Jinning Song
Lipid droplets (LDs), serving as the convergence point of energy metabolism and multiple signaling pathways, have garnered increasing attention in recent years. Different cell types within the central nervous system (CNS) can regulate energy metabolism to generate or degrade LDs in response to diverse pathological stimuli. This article provides a comprehensive review on the composition of LDs in CNS, their generation and degradation processes, their interaction mechanisms with mitochondria, the distribution among different cell types, and the roles played by these cells—particularly microglia and astrocytes—in various prevalent neurological disorders. Additionally, we also emphasize the paradoxical role of LDs in post-cerebral ischemia inflammation and explore potential underlying mechanisms, aiming to identify novel therapeutic targets for this disease.

13 July 2016 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
YZYonglin Zhao
Yonglin Zhao
YZYahui Zhao
Yahui Zhao
MZMing Zhang
Ming Zhang
JZJunjie Zhao
Junjie Zhao
XMXudong Ma
Xudong Ma
JSJinning Song
Jinning Song
Increasing evidence suggests that secondary injury after diffuse axonal injury (DAI) damages more axons than the initial insult, but the underlying mechanisms of this phenomenon are not fully understood. Recent studies show that toll-like receptor 4 (TLR4) plays a critical role in promoting adaptive immune responses and have been shown to be associated with brain damage. The purpose of this study was to investigate the role of the TLR4 signalling pathway in secondary axonal injury in the cortices of DAI rats. TLR4 was mainly localized in microglial cells and neurons, and the levels of TLR4 downstream signalling molecules, including TLR4, myeloid differentiation primary response gene 88, toll/IR-1-(TIR-) domain-containing adaptor protein inducing interferon-beta, interferon regulatory factor 3, interferonβ, nuclear factorκB (NF-κB) p65, and phospho-NF-κB p65, significantly increased and peaked at 1 d after DAI. Inhibition of TLR4 by TAK-242 attenuated apoptosis, neuronal and axonal injury, and glial responses. The neuroprotective effects of TLR4 inhibition were associated with decreases in the levels of TLR4 downstream signalling molecules and inflammatory factors, including interleukin-1β, interleukin-6, and tumour necrosis factor-α. These results suggest that the TLR4 signalling pathway plays an important role in secondary injury and may be an important therapeutic target following DAI.

1 February 2019 in World Neurosurgery
Verified
Journal Article
Closed access
JYJing Yuan
Jing Yuan
JQJianxun Qu
Jianxun Qu
DZDong Zhang
Dong Zhang
XLXingju Liu
Xingju Liu
JLJiaxi Li
Jiaxi Li
PGPeiyi Gao
Peiyi Gao

13 September 2025 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
YZYunfei Zhou
Yunfei Zhou
LZLongxiao Zhang
Longxiao Zhang
XYXinyang Yan
Xinyang Yan
ZYZhongbo Yang
Zhongbo Yang
ZKZhiyan Kou
Zhiyan Kou
JLJiaxi Li
Jiaxi Li

15 February 2017 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
YZYonglin Zhao
Yonglin Zhao
JZJunjie Zhao
Junjie Zhao
MZMing Zhang
Ming Zhang
YZYahui Zhao
Yahui Zhao
JLJiaxi Li
Jiaxi Li
JSJinning Song
Jinning Song
Treatment of diffuse axonal injury (DAI) remains challenging in clinical practice due to the unclear pathophysiological mechanism. Uncontrolled, excessive inflammation is one of the most recognized mechanisms that contribute to the secondary injury after DAI. Toll like receptor 2 (TLR2) is highlighted for the initiation of a vicious self-propagating inflammatory circle. However, the role and detailed mechanism of TLR2 in secondary injury is yet mostly unknown. In this study, we demonstrated the expression of TLR2 levels in cortex, corpus callosum, and internal capsule and the localization of TLR2 in neurons and glial cells in rat DAI models. Intracerebral knockdown of TLR2 significantly downregulated TLR2 expression, attenuated cortical apoptosis, lessened glial response, and reduced the secondary axonal and neuronal injury in the cortex by inhibiting phosphorylation of mitogen-activated protein kinases (MAPK) including Erk, JNK, and p38, translocation of NF-κB p65 from the cytoplasm to the nucleus, and decreasing levels of proinflammatory cytokines including interleukin-6, interleukin-1β, and tumor necrosis factor-α. On the contrary, administration of TLR2 agonist to DAI rats achieved an opposite effect. Collectively, we demonstrated that TLR2 was involved in mediating secondary injury after DAI by inducing inflammation via the MAPK and NF-κB pathways.